BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 30187571)

  • 1. Serum ferritin is not a reliable predictor to determine iron overload in thalassemia major patients post-hematopoietic stem cell transplantation.
    Jarisch A; Salzmann-Manrique E; Cario H; Grosse R; Soerensen J; Fischer R; Schulz A; Hammerstingl R; Wunderlich A; Bader P
    Eur J Haematol; 2018 Dec; 101(6):791-797. PubMed ID: 30187571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron overload in patients receiving allogeneic hematopoietic stem cell transplantation: quantification of iron burden by a superconducting quantum interference device (SQUID) and therapeutic effectiveness of phlebotomy.
    Busca A; Falda M; Manzini P; D'Antico S; Valfrè A; Locatelli F; Calabrese R; Chiappella A; D'Ardia S; Longo F; Piga A
    Biol Blood Marrow Transplant; 2010 Jan; 16(1):115-22. PubMed ID: 19766730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One-year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation.
    Inati A; Kahale M; Sbeiti N; Cappellini MD; Taher AT; Koussa S; Nasr TA; Musallam KM; Abbas HA; Porter JB
    Pediatr Blood Cancer; 2017 Jan; 64(1):188-196. PubMed ID: 27576370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limitations of serum ferritin to predict liver iron concentration responses to deferasirox therapy in patients with transfusion-dependent thalassaemia.
    Porter JB; Elalfy M; Taher A; Aydinok Y; Lee SH; Sutcharitchan P; El-Ali A; Han J; El-Beshlawy A
    Eur J Haematol; 2017 Mar; 98(3):280-288. PubMed ID: 27859648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-life experience with liver iron concentration R2 MRI measurement in patients with hemoglobinopathies: baseline data from LICNET.
    Vitrano A; Calvaruso G; Tesé L; Gioia F; Cassarà F; Campisi S; Butera F; Commendatore V; Rizzo M; Santoro V; Cigna V; Quota A; Bagnato S; Argento C; Fidone C; Schembari D; Gerardi C; Barbiera F; Bellisssima G; Giugno G; Polizzi G; Rosso R; Abbate G; Caruso V; Chiodi E; Gamberini MR; Giorgi B; Putti MC; Filosa A; De Ritis MR; Oliva E; Arcadi N; Fustaneo M; Mistretta L; Di Maggio R; Sacco M; Veronica DS; Giangreco A; Maggio A
    Eur J Haematol; 2016 Oct; 97(4):361-70. PubMed ID: 26818147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurement of liver iron concentration by superconducting quantum interference device biomagnetic liver susceptometry validates serum ferritin as prognostic parameter for allogeneic stem cell transplantation.
    Jacobi N; Herich L
    Eur J Haematol; 2016 Oct; 97(4):336-41. PubMed ID: 26800433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of vitamin C as an adjuvant therapy to different iron chelators in young β-thalassemia major patients: efficacy and safety in relation to tissue iron overload.
    Elalfy MS; Saber MM; Adly AA; Ismail EA; Tarif M; Ibrahim F; Elalfy OM
    Eur J Haematol; 2016 Mar; 96(3):318-26. PubMed ID: 26018112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ferritin trends do not predict changes in total body iron in patients with transfusional iron overload.
    Puliyel M; Sposto R; Berdoukas VA; Hofstra TC; Nord A; Carson S; Wood J; Coates TD
    Am J Hematol; 2014 Apr; 89(4):391-4. PubMed ID: 24347294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum ferritin underestimates liver iron concentration in transfusion independent thalassemia patients as compared to regularly transfused thalassemia and sickle cell patients.
    Pakbaz Z; Fischer R; Fung E; Nielsen P; Harmatz P; Vichinsky E
    Pediatr Blood Cancer; 2007 Sep; 49(3):329-32. PubMed ID: 17554789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Tissue Elastography With Magnetic Resonance Imaging T2* and Serum Ferritin Quantification in Detecting Liver Iron Overload in Patients With Thalassemia Major.
    Pipaliya N; Solanke D; Parikh P; Ingle M; Sharma R; Sharma S; Sawant P
    Clin Gastroenterol Hepatol; 2017 Feb; 15(2):292-298.e1. PubMed ID: 27650324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase II, Multicenter, Single-Arm Study to Evaluate the Safety and Efficacy of Deferasirox after Hematopoietic Stem Cell Transplantation in Children with β-Thalassemia Major.
    Yesilipek MA; Karasu G; Kaya Z; Kuskonmaz BB; Uygun V; Dag I; Ozudogru O; Ertem M
    Biol Blood Marrow Transplant; 2018 Mar; 24(3):613-618. PubMed ID: 29155313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High prevalence of iron overload in adult allogeneic hematopoietic cell transplant survivors.
    Majhail NS; DeFor T; Lazarus HM; Burns LJ
    Biol Blood Marrow Transplant; 2008 Jul; 14(7):790-4. PubMed ID: 18541198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of cardiac and hepatic iron overload in thalassemia major patients with T2* magnetic resonance imaging.
    Wahidiyat PA; Liauw F; Sekarsari D; Putriasih SA; Berdoukas V; Pennell DJ
    Hematology; 2017 Sep; 22(8):501-507. PubMed ID: 28218005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver fibrosis in young Egyptian beta-thalassemia major patients: relation to hepatitis C virus and compliance with chelation.
    Elalfy MS; Esmat G; Matter RM; Abdel Aziz HE; Massoud WA
    Ann Hepatol; 2013; 12(1):54-61. PubMed ID: 23293194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myocardial and liver iron overload, assessed using T2* magnetic resonance imaging with an excel spreadsheet for post processing in Tunisian thalassemia major patients.
    Ouederni M; Ben Khaled M; Mellouli F; Ben Fraj E; Dhouib N; Yakoub IB; Abbes S; Mnif N; Bejaoui M
    Ann Hematol; 2017 Jan; 96(1):133-139. PubMed ID: 27730342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Iron Overload and Iron Chelation with Deferasirox on Outcomes of Patients with Severe Aplastic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation.
    Pan T; Ji Y; Liu H; Tang B; Song K; Wan X; Yao W; Sun G; Wang J; Sun Z
    Transplant Cell Ther; 2023 Aug; 29(8):507.e1-507.e8. PubMed ID: 37116582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S; Pathare AV
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Curative effects and safety of deferasirox in treatment of iron overload in children with β-thalassemia major].
    Gao HY; Li Q; Chen JJ; Chen GF; Li CG
    Zhongguo Dang Dai Er Ke Za Zhi; 2011 Jul; 13(7):531-4. PubMed ID: 21752315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Deferasirox (Exjade®) in Modulation of Iron Overload in Patients with β-Thalassemia Intermedia.
    Karimi M; Arandi N; Haghpanah S; Ansari S; Azarkeyvan A; Bordbar M; Safaei S
    Hemoglobin; 2015; 39(5):327-9. PubMed ID: 26114738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassaemia and sickle cell disease.
    Voskaridou E; Douskou M; Terpos E; Papassotiriou I; Stamoulakatou A; Ourailidis A; Loutradi A; Loukopoulos D
    Br J Haematol; 2004 Sep; 126(5):736-42. PubMed ID: 15327528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.